- Home
- LCFY vs SLXN Comparison
LCFY vs SLXN Comparison
Compare LCFY & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- SLXN
- Stock Information
- Founded
- LCFY 2009
- SLXN 2008
- Country
- LCFY Australia
- SLXN Israel
- Employees
- LCFY N/A
- SLXN N/A
- Industry
- LCFY
- SLXN
- Sector
- LCFY
- SLXN
- Exchange
- LCFY Nasdaq
- SLXN NYSE
- Market Cap
- LCFY 7.3M
- SLXN 5.0M
- IPO Year
- LCFY 2022
- SLXN N/A
- Fundamental
- Price
- LCFY $7.26
- SLXN $1.36
- Analyst Decision
- LCFY
- SLXN Strong Buy
- Analyst Count
- LCFY 0
- SLXN 1
- Target Price
- LCFY N/A
- SLXN $9.00
- AVG Volume (30 Days)
- LCFY 24.4K
- SLXN 32.1M
- Earning Date
- LCFY 04-01-2025
- SLXN 02-21-2025
- Dividend Yield
- LCFY N/A
- SLXN N/A
- EPS Growth
- LCFY N/A
- SLXN N/A
- EPS
- LCFY N/A
- SLXN N/A
- Revenue
- LCFY $2,668,385.00
- SLXN N/A
- Revenue This Year
- LCFY N/A
- SLXN N/A
- Revenue Next Year
- LCFY N/A
- SLXN N/A
- P/E Ratio
- LCFY N/A
- SLXN N/A
- Revenue Growth
- LCFY N/A
- SLXN N/A
- 52 Week Low
- LCFY $2.20
- SLXN $0.21
- 52 Week High
- LCFY $11.23
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- LCFY 44.93
- SLXN N/A
- Support Level
- LCFY $7.05
- SLXN N/A
- Resistance Level
- LCFY $8.00
- SLXN N/A
- Average True Range (ATR)
- LCFY 0.62
- SLXN 0.00
- MACD
- LCFY -0.15
- SLXN 0.00
- Stochastic Oscillator
- LCFY 13.18
- SLXN 0.00
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.